The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial showed that the direct thrombin inhibitor bivalirudin, with provisional glycoprotein (Gp) IIb/IIIa ...

These drugs include abciximab, eptifibatide and tirofiban. Glycoprotein IIb/IIIa inhibitors very strongly inhibit platelet function by blocking fibrinogen binding to the activated glycoprotein IIb ...

The currently available antiplatelet drugs target key steps of platelet activation including thromboxane A 2 synthesis, ADP-mediated signaling, and glycoprotein IIb/IIIa-mediated platelet aggregation.